ジャーナル: Science / 年: 2020 タイトル: Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. 著者: Philip J M Brouwer / Tom G Caniels / Karlijn van der Straten / Jonne L Snitselaar / Yoann Aldon / Sandhya Bangaru / Jonathan L Torres / Nisreen M A Okba / Mathieu Claireaux / Gius Kerster / ...著者: Philip J M Brouwer / Tom G Caniels / Karlijn van der Straten / Jonne L Snitselaar / Yoann Aldon / Sandhya Bangaru / Jonathan L Torres / Nisreen M A Okba / Mathieu Claireaux / Gius Kerster / Arthur E H Bentlage / Marlies M van Haaren / Denise Guerra / Judith A Burger / Edith E Schermer / Kirsten D Verheul / Niels van der Velde / Alex van der Kooi / Jelle van Schooten / Mariëlle J van Breemen / Tom P L Bijl / Kwinten Sliepen / Aafke Aartse / Ronald Derking / Ilja Bontjer / Neeltje A Kootstra / W Joost Wiersinga / Gestur Vidarsson / Bart L Haagmans / Andrew B Ward / Godelieve J de Bree / Rogier W Sanders / Marit J van Gils / 要旨: The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are ...The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007 micrograms per milliliter. Competition and electron microscopy studies illustrate that the SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes. In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention.